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A Restricted Repertoire of De Novo Mutations
in ITPR1 Cause Gillespie Syndrome
with Evidence for Dominant-Negative Effect
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Joe Rainger,2,3 Abhijit Dixit,8 Ajoy Sarkar,8 Eduardo Lo´pez Laso,13 Rocio Sanchez-Carpintero,14
Jesus Barrio,20 Pierre Bitoun,4 Trine Prescott,5 Ruth Riise,6 Shane McKee,7 Jackie Cook,10 Lisa McKie,2
Berten Ceulemans,21 Franc¸oise Meire,22 I. Karen Temple,11 Fabienne Prieur,12 Jonathan Williams,17
Penny Clouston,17 Andrea H. Ne´meth,19 Siddharth Banka,16 Hemant Bengani,2 Mark Handley,2
Elisabeth Freyer,2 Allyson Ross,2 DDD Study,15 Veronica van Heyningen,2 Joseph A. Marsh,2,24
Frances Elmslie,1,24 and David R. FitzPatrick2,24,*
Gillespie syndrome (GS) is characterized by bilateral iris hypoplasia, congenital hypotonia, non-progressive ataxia, and progressive cere-
bellar atrophy. Trio-based exome sequencing identified de novo mutations in ITPR1 in three unrelated individuals with GS recruited to
the Deciphering Developmental Disorders study. Whole-exome or targeted sequence analysis identified plausible disease-causing ITPR1
mutations in 10/10 additional GS-affected individuals. These ultra-rare protein-altering variants affected only three residues in ITPR1:
Glu2094missense (one de novo, one co-segregating), Gly2539missense (five de novo, one inheritance uncertain), and Lys2596 in-frame
deletion (four de novo). No clinical or radiological differences were evident between individuals with differentmutations. ITPR1 encodes
an inositol 1,4,5-triphosphate-responsive calcium channel. The homo-tetrameric structure has been solved by cryoelectron microscopy.
Using estimations of the degree of structural change induced by known recessive- and dominant-negative mutations in other disease-
associated multimeric channels, we developed a generalizable computational approach to indicate the likely mutational mechanism.
This analysis supports a dominant-negative mechanism for GS variants in ITPR1. In GS-derived lymphoblastoid cell lines (LCLs), the
proportion of ITPR1-positive cells using immunofluorescence was significantly higher in mutant than control LCLs, consistent with
an abnormality of nuclear calcium signaling feedback control. Super-resolution imaging supports the existence of an ITPR1-lined nucle-
oplasmic reticulum.Mice with Itpr1 heterozygous null mutations showed nomajor iris defects. Purkinje cells of the cerebellum appear to
be the most sensitive to impaired ITPR1 function in humans. Iris hypoplasia is likely to result from either complete loss of ITPR1 activity
or structure-specific disruption of multimeric interactions.Ida Mann, in her classic 1925 paper on the development of
the iris in human embryos and fetuses,1 describes four
major morphological stages. From 28 to 49 gestational
days (gd), there is formation of the annular irido-hyaloid
vessel at the distal rim of the optic cup, coincident with
the apposition of the optic fissure and appearance of the
lens placode. Between 50 and 77 gd, after the separation
of the lens vesicle, the ‘‘mesodermal’’ iris appears as a
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chyme surrounding the hyaloid vessels. From 78 to
84 gd, the ectodermal iris appears as a separate outgrowth
from the tip of the optic cup coinciding with the disap-
pearance of the irido-hyaloid vessels. The final stage,
from 85 to 175 gd, involves growth of the ectodermal
iris, the outer and inner layers of which are contiguous
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Figure 1. Human Genetic, Ophthalmic, and Radiological Features of Gillespie Syndrome
(A) Diagrammatic representation of the Sanger sequencing chromatograms in 12 families in this studywith a confident clinical diagnosis
of Gillespie syndrome. In 9/12, de novo status of the mutations could be confirmed and in one family (SVP_SW), the mutation was in-
herited from an affected mother.
(B) Left: Image of the right eyes from individuals 263220 and 5284_5284 showing iris hypoplasia and iridolenticular strands (arrowed)
typical of Gillespie syndrome.Middle: MR brain imaging of individual 261348 at the age of 1 year 7 months showingminor prominence
of the cerebellar folia of the vermis superiorly but by 4 years 8months progressive cerebellar vermian volume loss andminor prominence
of the superior cerebellar folia of both cerebellar hemispheres. Minor periventricular high T2/FLAIR signal adjacent to frontal and occip-
ital horns (white arrowheads). Right: MR brain imaging of individual 5285_5285 aged 11 years 7 months showing moderate vermis and
(legend continued on next page)
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retina, respectively. Both layers of the ectodermal iris even-
tually pigment. The sphincter muscles appear to develop
from cells of the distal outer layer supplied by radial vessels
from the mesodermal iris. The dilator musculature de-
velops as a thin layer growing radially on the surface on
the outer layer of the ectodermal iris.
The best-studied malformation of the iris is complete
aniridia (MIM: 106210),2 with more than 90% of cases
caused by heterozygous loss-of-function (LOF) mutations
in the paired- and homeo-domain containing transcrip-
tion factor PAX6 (MIM: 607108). PAX6-associated aniridia
is, however, a pan-ocular disease typified by foveal hypo-
plasia, cataracts, and progressive corneal opacification in
addition to the iris anomaly.3 Extraocular disease is rare
in PAX6-associated aniridia although structural brain
anomalies and other sensory impairments have been iden-
tified.4 Apparently isolated aniridia has also been reported
in association with heterozygous LOFmutations in FOXC1
(MIM: 601090)5,6 and PITX2 (MIM: 601542),7 although
these loci are more commonly associated with anterior
segment dysgenesis (MIM: 602482).8 Syndromic forms of
aniridia have been described, the best known of which is
WAGR (Wilms tumor, aniridia, genital malformations, in-
tellectual disability [retardation] [MIM: 194072]) resulting
from a contiguous gene defect encompassing PAX6 and
WT1 (MIM: 607102).9 The other well-known syndromic
form of aniridia is Gillespie syndrome (MIM: 206700).
Aniridia is, however, an incorrect description of iris malfor-
mation in Gillespie syndrome, which is a characteristic
form of iris hypoplasia with ‘‘scalloping’’ of the pupillary
edge. Gillespie syndrome typically presents as fixed dilated
pupils in affected infants. Iridolenticular strands can be
seen at regular intervals (Figure 1B) as can other remnants
of the pupillary membrane. From the description of the
embryology given above, the iris defect in Gillespie syn-
drome would thus be consistent with a failure of develop-
ment or maintenance of the sphincter musculature and
the associated stroma. The eye in Gillespie syndrome can
be further distinguished from PAX6-related disease by the
absence of foveal hypoplasia and corneal opacification.
The key extra-ocular features of Gillespie syndrome are
congenital hypotonia, non-progressive cerebellar hypopla-
sia, and ataxia (Figures 1B–1D) and variable, usually mild,
neurocognitive impairment. The inheritance of Gillespie
syndrome has been considered heterogeneous with both
autosomal-dominant and autosomal-recessive inheritance
being postulated on the basis of convincing patterns in in-cerebellar hemisphere atrophy, more prominent superiorly and in t
signal adjacent to the frontal horns as well as a couple of foci within
(C) Left: Right eye of individual 1388_1388 showing iris hypoplasia.
erate vermis and cerebellar atrophy, worse in the vermis and superior
the frontal horns (white arrowheads).
(D) Right eye of individual 91_91 at age 52 years (de novo c.6280G>C
adjacentMR imaging showsmild cerebellar volume loss (cerebellar he
increased T2/FLAIR signal, most notably adjacent to the frontal horn
where in the white matter mainly of the centrum semiovale. There
appears normal.
The Amdividual families.10,11 The clinical features of 13 affected
individuals with a confident clinical diagnosis of Gillespie
syndrome who were used in themolecular studies reported
below are summarized in Table 1. We reviewed the avail-
able neuroimaging of each case subject, which showed
that the cerebellar vermis atrophy is present early and
is progressive particularly in the first 5 years of life
(Figures 1B–1D). The atrophy mainly affected the superior
vermis progressing to involve the superior cerebellar
hemispheres more than the inferior aspects. Abnormal
periventricular increased T2/FLAIR white matter signal
was seen adjacent to the frontal horns on all examina-
tions and older individuals also had scattered foci of
increased T2/FLAIR signal in the white matter, mainly
frontally. Until now the molecular basis of Gillespie syn-
drome was not known, with causative mutations in
PAX6, FOXC1, and PITX2 having been excluded in many
reported cases.12
Deciphering Developmental Disorders (DDD) is a UK-
and Ireland-wide project that aims to use whole-exome
sequencing to identify the cause of previously unexplained
severe and extreme phenotypes that plausibly have their
genesis in embryogenesis or early fetal brain develop-
ment.13 The study has UK Research Ethics Committee
approval (10/H0305/83, granted by the Cambridge South
REC, and GEN/284/12 granted by the Republic of Ireland
REC) with written consent being obtained from all partici-
pating families. To date, 13,936 probands have been re-
cruited with DNA samples available in the majority from
the affected individual and both parents (trios). Three indi-
viduals have been recruited to DDD with a clinical diag-
nosis of Gillespie syndrome (261348, 263220, 272179;
Figure 1A) and these were whole-exome sequenced as
part of the first 4,294 trios. The technical and analytical
details of the trio exome analysis used in DDD have been
previously reported.14–16 In brief, fragmented genomic
DNA was the substrate for targeted pull-down using a
custom Agilent SureSelect 55MB Exome Plus and 75-base
paired-end sequenced on Illumina HiSeq. Alignment was
performed with Burrows-Wheeler Aligner (BWA v.0.59)
and realignment around indels with GATK. Putative
de novo mutations were identified from exome data with
DeNovoGear software.17 The functional consequence of
each variant was assessed using the most severe conse-
quence from Ensembl Variant Effect Predictor (VEP).18
Plausibly pathogenic mutations in known developmental
disorders were identified by filtering by gene and alleliche vermis with minor increased periventricular white matter T2
the frontal lobe white matter bilaterally (white arrowheads).
Right: Individual 272179 at age 37 years. MR brain showing mod-
ly. Abnormal periventricular increased T2/FLAIR signal adjacent to
[p.Glu2094Gln]) showing iris hypoplasia with fixedmydriasis. The
mispheres and vermis), more so superiorly. There is periventricular
s with multiple foci of white matter increased T2/FLAIR signal else-
is a minor degree of generalized cerebral atrophy. Gyral pattern
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Table 1. Summary of the Clinical and Molecular Finding in Individuals with Gillespie Syndrome
Residue Involved Glu2094 Gly2539
ID 91_91 SVP SW 261348 263220 2021_2021
Genomic mutation hg19 chr3 g.4821267G>C chr3 g.4821268A>G chr3 g.4856205G>C chr3 g.4856205G>A chr3 g.4856205G>A
Genotype het het het het het
Mutation type missense variant missense variant missense variant missense
variant
missense
variant
NM_001168272.1;
ENST00000302640
c.6280G>C c.6281A>G c.7615G>C c.7615G>A c.7615G>A
NP_001161744.1;
ENSP00000306253.8
consequence
p.Glu2094Gln p.Glu2094Gly p.Gly2539Arg p.Gly2539Ar) p.Gly2539Ar)
De novo mutation yes NK mat yes yes yes
Sex female female female male female female
Prenatal Growth
Gestation NK NK NK 40 40 40
Birth weight (SD) NK NK ‘‘normal’’ 0.76 1.09 0.99
Postnatal Growth
Age (year) 55 34 13 7.19 14.62 28
Height_SD 0.53 NK NK 0.38 NK NK
Weight_SD 2.31 NK NK 0.19 NK NK
OFC_SD 0.35 NK NK 0.89 60.7 NK
Neurology and Development
Sat independently late NK NK 2 years 2–2.5 years 13 months
Walked independently 8–9 years NK NK 10 years not yet
achieved
>6 years
Speech delay yes NK NK severe yes moderate
Intellectual disability mild to moderate learning
difficulties
mild learning
difficulties
mild mild to
moderate
Hypotonia NK NK yes no yes yes
Ataxia yes yes yes yes yes yes
Cerebellar hypoplasia/
atrophy
yes yes yes yes yes yes
Ophthalmology
Bilateral iris hypoplasia yes yes yes yes yes yes
Foveal hypoplasia no NK NK NK yes NK
Visual impairment mild NK NK NK mild NK
Negative PAX6 screen yes exome exome yes yes yes
Clinical Diagnosis of
Gillespie syndrome
yes yes yes yes yes yes
Other Features
Other clinical features gastroesophageal
reflux, depression
none none gastresophageal
reflux
scoliosis,
gall stones
none
Abbreviations are as follows: NK, not known; Het, heterozygous variant; SD, standard deviation; OFC, occipito-frontal circumference.
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Gly2539 Lys2596
2018_2018 5284_5284 5285_5285 272179 291_291 2374_2374 1388_1388
chr3 g.4856205G>A chr3 g.4856205G>A chr3 g.4856205G>A chr3 g.4856866_
4856868delAAG
chr3 g.4856866_
4856868delAAG
chr3 g.4856866_
4856868delAAG
chr3 g.4856866_
4856868delAAG
het het het het het het het
missense variant missense variant missense variant inframe deletion inframe deletion inframe deletion inframe deletion
c.7615G>A c.7615G>A c.7615G>A c.7786_
7788delAAG
c.7786_
7788delAAG
c.7786_7788delAAG c.7786_7788delAAG
p.Gly2539Ar) p.Gly2539Ar) p.Gly2539Ar) p.Lys2596del p.Lys2596del p.Lys2596del p.Lys2596del
NK yes yes yes yes yes yes
female female male male female female female
NK 40 NK 37 40 40 37
NK 1.17 NK 1.25 1.17 0.75 0.04
NK 3.4 12 36.95 10 16 19.75
NK 3.12 NK NK 3 4.2 1
NK 1.7 NK NK 2 NK 1.8
NK 0.58 NK 2.39 NK NK 2
NK 9 months NK late 18 months 3 years 30 months
NK not yet achieved NK 10 years not yet achieved >10 years 7 years
NK NK NK moderate-severe yes yes yes
NK mild moderate mild-moderate global delay global delay mild
NK yes yes yes yes yes yes, severe
yes yes yes yes yes yes yes, severe
NK yes yes yes yes yes yes
yes yes yes yes yes yes yes
NK NK NK no NK no no
NK mild NK NK mild moderate NK
yes no no yes yes yes yes
yes yes yes yes yes yes yes
none patent foramen
ovale and a mild
pulmonary valve
stenosis
none scoliosis,
macrocephaly,
small ears
none frontal bossing slight facial
dysmorphism
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requirement using the DDG2P database combined with
the minor allele frequencies as described.16 Using this
approach, each of the Gillespie syndrome case subjects in
DDD was found to carry a single plausible pathogenic
variant, which was a de novo protein-altering mutation
in ITPR1 (MIM: 147265). Two of these individuals
(261348 and 263220) had different heterozygous muta-
tions affecting the same reference base (261348: chr3
g.4856205G>C; 263220: chr3 g.4856205G>A [hg19]),
which is predicted to result in an identical change in the
open reading frame (p.Gly2539Arg). The latter of these
genomic mutations (chr3 g.4856205G>A) is recorded in
1/120,716 (0.000008284) alleles in the ExAC database in
an individual of recent African decent, although the inher-
itance or any associated phenotype of the carrier is not
available. Individual 272179 had a heterozygous in-
frame deletion of a single codon (chr3 g.4856866_
4856868delAAG [p.Lys2596del]). The BAM and VCF files
from the first 4,294 trios in the DDD project are available
via the European Genome-Phenome Archive (EGA). All
residue numbering uses reference sequence GenBank: NP_
001161744.1 (Q14643-2; ENSP00000306253.8), which
represents ITPR1 isoform 2 with a total of 2,743 amino
acids and lacking a 15 amino acid insertion at Asp321.
The de novo status of each of these variants was confirmed
via an independent sequencing technology (Sanger or
Illumina MiSeq). On review of the exome data, no other
plausibly pathogenic variant could be identified on the
second allele in each of the three DDD case subjects.
After identification of the de novo ITPR1 mutations
in the DDD case subjects, we reviewed whole-exome se-
quences that had been independently generated on a pre-
viously reported19,20 mother (SVP) and daughter (SW) with
Gillespie syndrome. The exome capture had been per-
formed with the SureSelectXT Human All Exon V5þUTRs
kit (Agilent) followed by 150-base paired-end sequencing
on a NextSeq 500 (Illumina). The CLC Genomics Work-
bench v.7.5 was used for read mapping against GRCh37/
hg19, followed by duplicate read removal and coverage
analysis for all regions enriched with the SureSelect XT
exome kit. Approximately 98% of the target regions were
covered in both individuals. A read depth of at least 103
was obtained for 80.26% and 90.75% of the SureSelect
target regions in both affected individuals, respectively.
Finally, quality-based variant calling and annotation was
performed and the resulting variant lists were exported
for filtering. SVP and SW shared a single, heterozygous,
ultra-rare missense mutation (not present in ExAC or
1000 Genomes data) in ITPR1 (chr3 g.4821268A>G
[p.Glu2094Gly]) (Supplemental Data). This study was con-
ducted according to the tenets of Helsinki, and written
informed consent was obtained from the participating
family.
Eight additional unrelated cases of Gillespie syndrome
were identified via the eye malformation cohort held in
the MRC Human Genetics Unit (MRC HGU) at the Univer-
sity of Edinburgh, a study approved by the UK Multire-986 The American Journal of Human Genetics 98, 981–992, May 5, 2gional Ethics Committee (Reference: 06/MRE00/76) with
written informed consent obtained from the participating
families. Whole-exome sequencing was available on one
of these individuals (1388_1388) which, on review, was
found to show a heterozygous mutation in ITPR1 identical
to the chr3 g.4856866_4856868delAAG (p.Lys2596del)
allele mentioned above (individual 1388_1388 is the
same individual as F4:II2 who is described, with the same
ITPR1 mutation, in the accompanying report by Gerber
et al.21). This mutation was subsequently shown to have
occurred as a de novo mutation in this individual.
No other plausible disease-causing mutations were identi-
fied in ITPR1 from these exome analyses. Targeted re-
sequencing was performed in the seven other individuals
with a confident clinical diagnosis of Gillespie syndrome.
Six exons of ITPR1 were selected: coding exons 46 and 52
to 56, which encode the region spanning Glu2094 and
the entire calcium ion channel domain, respectively (Table
S2). This revealed heterozygous mutations in all seven
affected individuals: 4/7, c.7615G>A (p.Gly2539Arg);
2/7, c.7786_7788delAAG (p.Lys2596del); and 1/7, chr3
g.4821267G>C (p.Glu2094Gln) (Figure 1A). In 6/7 of
these individuals, the mutation was not present in DNA
from the mother and father (all clinically unaffected) and
biological relationships were confirmed with highly infor-
mative genetic markers suggesting that the mutations had
occurred de novo in the affected individual. In 2018_2018,
themutation was not present in the unaffectedmother but
the father’s DNA sample was not available for analysis. A
separate cohort of 173 individuals with non-syndromic
aniridia and with no mutation in PAX6 detected were
screened for mutations in ITPR1 using the targeted rese-
quencing amplicons. No plausible disease-causing muta-
tions were identified, suggesting that ITPR1 mutations
are specific for iris hypoplasia associated with Gillespie
syndrome and that this locus does not contribute to other
forms of aniridia. Thus, all 13 affected individuals with a
clinical diagnosis of Gillespie syndrome that were available
to us for study were found to have ultra-rare protein-
altering variations affecting only three residues in ITPR1,
with at least ten of these mutations having occurred
de novo.
ITPR1 encodes a calcium-release channel that is inositol
1,4,5-trisphosphate (IP3) responsive. Heterozygous LOF
mutations, mostly deletions encompassing ITPR1, have
been identified in spinocerebellar ataxia type 15 (SCA15
[MIM: 606658]). SCA15 is characterized by very slowly
progressive autosomal-dominant cerebellar ataxia and
cerebellar atrophy.22–27 Haploinsufficiency for ITPR1 ac-
counted for 2% of dominant ataxia in a screen of a large se-
ries of well-characterized families with the age of onset in
the affected individuals with ITPR1 deletions in this series
being between 18 and 66 years.24 Earlier-onset ITPR1-asso-
ciated cerebellar disease has been reported. In two families
with a congenital, non-progressive spinocerebellar ataxia
(SCA29 [MIM: 117360]), the disease was found to co-segre-
gate with a different ultra-rare ITPR1missense mutation in016
Figure 2. De Novo Mutations Affecting Three Residues in ITPR1 Are the Major Cause of Gillespie Syndrome
(A) Linear representation of ITPR1. Amino acid numbering is based on GenBank: NP_001161744.1 (Q14643-2; ENSP00000306253.8),
which has 2,743 residues (encoded by the canonical transcript GenBank: NM_001168272.1; ENST00000302640). The colored boxes
represent the following domains and features: green, ligand transferase domain; red, inositol 1,4,5-triphosphate binding domain; yellow,
15 amino acid insertion in isoform Q14643-1 (which has 2,758 residues); brown, RyR and IP3R homology domain; orange, intracellular
transmembrane domain; blue, calcium ion transport channel. The heterozygous mutations associated with congenital cerebellar ataxia
(blue text) mostly cluster toward the N terminus at the ligand transferase and inositol 1,4,5-triphosphate binding domains, whereas
those associated with autosomal-dominant Gillespie syndrome (pink text) cluster toward the C terminus at or near the intracellular
transmembrane domain and calcium ion transport channel.
(B) Structure of the ITPR1 tetramer, left, and monomer, right (derived from PDB: 3JAV). The three mutation sites from this study asso-
ciated with Gillespie syndrome shown in red, and six sites previously associated with other disorders shown in blue.each family (encoding c.1759A>G [p.Asn587Asp] and
c.4639G>A [p.Val1547Met]; these and all subsequent
numbering converted to GenBank: NP_001161744.1
[Q14643-2, ENSP00000306253.8] with pathogenicity
scores for all variants provided in Table S3).28 Another
multigeneration family with c.4639G>A (p.Val1547Met)
and a mild phenotype have been described.29 More re-
cently, de novo missense mutations have been found in
infantile onset spinocerbellar ataxia (encoding c.800C>G
[p.Thr267Arg], c. 800C>T [p.Thr267Met], c.830G>T
[p.Ser277Ile], c.1736C>T [p.Thr579Ile])30 and ataxic cere-
bral palsy (encoding c.1759A>G [p.Asn587Asp], c.4459_
4460delinsGA [p.Ser1487Asp]).31 In total, eight intragenic
mutations, substituting seven residues, have been identi-The Amfied in 12 unrelated cases of cerebellar ataxia, with only
one of these cases having an adult-onset phenotype
(Figure 2). It is notable that the more severe and earlier-
onset ITPR1-associated ataxia is caused predominantly by
missense variants and that these missense variants are
distinct from those associated with Gillespie syndrome.
When trying to understand the molecular origins of the
dominant phenotype, it is interesting to note that a domi-
nant-negative effect has been described for mutations in
several other transmembrane channel genes.32–34 Thus
we can hypothesize that a similar mechanism might ac-
count for the effects of the mutations identified here.
Given that ITPR1 forms a homotetramer (Figure 2B),
then only 1/16 assembled tetramers will contain fourerican Journal of Human Genetics 98, 981–992, May 5, 2016 987
wild-type subunits, in the absence of any cotranslational
assembly.35 If a single variant subunit can block channel
function, then 94% of tetramers will be non-functional,
thus potentially explaining the dominant phenotype.
We were unaware of any methods for predicting
whether protein-altering mutations are likely to show a
dominant-negative effect and we speculated that such
variants should generally be less structurally perturbing
than other LOF pathogenic mutations, because a domi-
nant-negative mechanism requires the complex to at
least partially assemble. To address this, we predicted the
structural destabilization36 of pathogenic missense muta-
tions with a known or likely dominant-negative mecha-
nism from proteins that form transmembrane channels
and compared them to recessive mutations from the
same proteins or dominant mutations from genes with
no known dominant-negative effect (Figure S1). We
observe a highly significant difference (p % 0.0015)
with the dominant-negative mutations inducing a lesser
change in protein stability than the two other groups of
mutations.
Next, using the recently determined cryoelectron micro-
scopy structure of the tetrameric ITPR1 protein,37 we pre-
dicted the effects of the missense mutations identified in
this study, as well as the cerebellar ataxia-associated
missense mutations mentioned above. All but one of the
ITPR1mutations are predicted to have mildly destabilizing
effects (Table S1). We compared these mutations to a
larger set of known dominant-negative mutations in trans-
membrane channels, recessive mutations in the same
transmembrane channels, and other dominant mutations
with no known dominant-negative association (Figure S1).
We observe that the dominant-negative mutations are
significantly less destabilizing than the other groups. The
pathogenic missense mutations in ITPR were found to be
most similar to known dominant-negative mutations us-
ing these parameters. Only p.Gly2539Arg is predicted to
be strongly destabilizing, although it is still within the
range of some of the other known dominant-negative mu-
tations. Additional evidence for the pathogenicity of
p.Gly2539Arg comes from its position immediately N-ter-
minal to the ion selectivity filter of the ITPR1 protein.38
Indeed, site-directed mutagenesis of Gly2539 to alanine
has demonstrated a loss of channel activity in a number
of in vitro assays.39 Overall, this analysis strongly supports
a dominant-negative mechanism for the mutations identi-
fied here, as has been observed in other transmembrane
channels.
We can also consider how the different ITPR1mutations
are located with respect to the three-dimensional structure
of the complex (Figure 2B). Interestingly, all three residues
altered in Gillespie syndrome are located near the center
of the channel, within or close to the transmembrane re-
gion, whereas all of the non-Gillespie mutations occur
away from the center within the cytoplasmic domains.
Notably, 4/6 non-Gillespie positions are located at or
near the IP3 binding site.
37 The only point mutation988 The American Journal of Human Genetics 98, 981–992, May 5, 2associated with adult-onset ITPR1-associated ataxia (en-
coding p.Pro1068Leu) is located relatively near in space
to another early-onset mutation, and is also predicted to
be only mildly destabilizing, suggesting that it might also
be associatedwith a dominant-negativemechanism, rather
than the haploinsufficiency associated with SCA15 gene
deletions.
The dominant-negative hypothesis requires the mutant
protein to be translated, stable, and correctly targeted.
To assess this we used lymphoblastoid cell lines (LCLs)
that had been established from five of the affected
individuals with Gillespie syndrome. Two of these individ-
uals, 2021_2021 and 2018_2018, carried c.7615G>A
(p.Gly2539Arg) and three, 291_291, 2374_2374, and
1388_1388, had c.7786_7788delAAG (p.Lys2596del).
Western blot of protein extracted from unsynchronized
cultures revealed a variable level of ITPR1 between control
and mutant LCL with no obvious difference between the
groups (data not shown). Protein localization was assessed
using immunofluorescence staining with confocal micro-
scopy or structured illumination microscopy (SIM). As ex-
pected, punctate perinuclear staining was seen in both
control and mutant cell lines consistent with known
localization to the smooth endoplasmic reticulum40,41
(Figure 3A). ITPR1 is also known to localize to structures
within the nucleus known as the nucleoplasmic reticu-
lum.42,43 In the Gillespie syndrome LCLs, themost striking
difference compared to control LCLs was a consistently
higher proportion of cells that were positive ITPR1 via
immunofluorescence (Figure 3B). Using quantitative anal-
ysis of super-resolution SIM images, no significant differ-
ences could be detected in the number of fluorescence
foci or the total volume of the ITPR1-positive regions
within the whole cell or the nucleus (Figures 3C and S3).
The irregularities in the nuclear outline in the mutant cells
might be indicative of an increased number and/or
increased size of the nucleoplasmic reticular pores (see
Figure 4 in Lui et al.43). These changes might reflect failure
of a feedback loop caused by a deficit in calcium signaling
within the nucleus. However, we were unable to directly
assess ITPR1-associated calcium signaling in the LCLs us-
ing ATP because no stimulation of calcium signaling was
seen in either control or mutant cells (Figure S4).
Heterozygous null, non-mosaic, 16.5 dpc mouse em-
bryos and adult mice were created via CRISPR/Cas9
genome editing methodology (Supplemental Data). These
embryos displayed no obvious morphological differences
in the early development of the iris compared to their
wild-type littermates (Figure S2A). Immunohistochemistry
(IHC) of the wild-type mouse embryos revealed no evi-
dence of specific staining of ITPR1 in the developing
iris (data not shown). No change in PAX6 levels could
be detected between mutant and wild-type embryos
(Figure S2A). Two heterozygous null adult mice could be
examined at the age of 76 days with wild-type littermate
controls (Figure S2B). Although minor defects in the iris
were noted in both mice, no major anomalies that would016
Figure 3. Functional Characterization of ITPR1/Itpr1 Mutations
(A) Confocal imaging of lymphoblastoid cell lines (LCLs) showing representative examples from unaffected individuals (control 1 as an
exemplar) or individuals with Gillespie syndrome (291_291 and 2018_2018 as exemplars). The top panel shows DAPI-stained nuclei.
The panel below shows the punctate staining in the nuclear and perinuclear regions on immunofluorescence staining using an anti-
ITPR1 antibody. ITPR1mutant cells consistently showedmore punctate staining within the nucleus compared to the controls. The third
panel shows the merge of the first and second. The fourth panel shows super-resolution SIM imaging of representative LCL nuclei from
each of the genotypes,
(B) The number of ITPR1-stain-positive cells in LCLs with or without mutations in ITPR1 were analyzed with ImageJ. Area, shape
descriptor, and mean gray value were measured for each cell. In control LCLs, <20% of the DAPI-positive (þve) cells were also þve
for ITPR1 immunofluorescence. In cells carrying either of the indicated mutations, 30%–50% of the cells were ITPR1 positive. Chi-
squared tests of the difference between the mutant and control cells suggest these are very unlikely to be chance observations.
(C) Quantitative fluorescence analysis from 3D super-resolution images showing the mean total volume of ITPR1-positive foci for the
following compartments within the cell: whole cell, reticular component, whole nucleus, and low-DAPI regions of the nucleus. Multiple
individual cells from two independent LCLs derived from affected individuals per genotype were obtained via structured illumination
microscopy (SIM). Themasking strategy used to obtain these data is outlined in Figure S3. The error bars in this graph represent standard
error of the mean. No significant difference was observed between genotypes.be consistent with the phenotype seen in Gillespie syn-
drome could be detected. These data suggest that the role
of ITPR1 in iris development is either indirect, acting at a
later stage of development, or is tolerant of 50% residual
channel activity. The latter explanation would be consis-
tent with the lack of an iris phenotype in individuals
affected with SCA15 in whom haploinsufficiency for
ITPR1 is the predominant genetic mechanism. Of note,
Ca2þ has been implicated in development of the eye in
both chick and zebrafish, although the source of these
ions has been thought to be extracellular (as reviewed in
Webb and Miller44).
The data presented here provide strong evidence that
Gillespie syndrome is a clinically and neuroradiologically
distinct disorder that shows locus homogeneity. The
cerebellar anomalies in these case subjects are similar to
that seen in the SCA29 phenotype. We present evidenceThe Ambased on the predicted effect of mutations on the forma-
tion of multimeric channels that suggests that these
mutations are likely to be acting by a dominant-negative
effect. This protein-structure-based analysis is likely to
have wide applicability in the interpretation of mutations,
particularly in the important ‘‘channelopathy’’ class of
human disease genes.45–47 The iris hypoplasia, which
typifies Gillespie syndrome, might be a consequence of
lower level of residual function in ITPR1 (compared to
SCA29) but, given that only specific residues are altered,
it seems more likely that these mutations disrupt func-
tional interactions that are critical to the formation and/or
maintenance of the sphincter pupillae muscle. In this
regard it is interesting that mutations in the gene encod-
ing a smooth muscle actin (ACTA2 [MIM: 102620])
have recently been reported with a very similar iris
phenotype.48 ITPR1 and ATCA2 might interact in smootherican Journal of Human Genetics 98, 981–992, May 5, 2016 989
muscle as components of the cGMP kinase signaling
complex.49Supplemental Data
Supplemental Data include four figures and three tables and can
be found with this article online at http://dx.doi.org/10.1016/j.
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We mapped all human missense mutations annotated as pathogenic in Ensembl Variation 
81 against chains with >50% sequence identity in the Protein Data Bank (PDB) as of 2015-
10-21. Dominant, recessive and dominant-negative classifications came from Ensembl, 
OMIM and (ref.1). Dominant mutations from genes with a known dominant-negative effect 
were included in the dominant-negative group. We used FoldX to predict the change in 
protein subunit stability (G) for each mutation. For mutations that mapped to multiple 
different structures, we used the average G values. Boxes represent quartile distributions 
and whiskers extend up to 1.5x the interquartile range, with open circles representing 
outliers. Values for the ITPR1 mutations (Table S1) are shown with the dominant-negative 
group, coloured red for mutations identified in this study and blue for those identified 
previously. P-values are calculated with the Wilcoxon rank-sum test and show that 
dominant-negative mutations in transmembrane channel genes are significantly lower in 
predicted G compared to recessive mutations from the same set of genes, or dominant 
mutations from genes with no known dominant-negative association. The values at the 
bottom represent the probability that 11 mutations randomly selected from each group would 
have a lower mean G than the 11 ITPR1 mutations considered here, calculated from 107 
trials. This suggests that the ITPR1 mutations are most consistent with the dominant-
negative mutations and significantly less destabilizing than the recessive or other dominant 
mutations. If Lys2596del is ignored (since FoldX does not accurately predict the effects of 
deletions), then the probabilities change to 0.153, 0.0013 and 0.0094 for the three groups. 
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A. Saggital sections through the eyes of 16.5 dpc mouse embryos. Representative sections 
from the wildtype embryos (top, n=3) and the heterozygous Itpr1 null allele littermates 
(bottom, n=3) generated using CRISPR/Cas9 genomic editing.  Guide RNAs were designed 
to target coding exon 57 of Itpr1 (Itpr1_MS_gRNA_1 5’-
CACCGCAGTGACGATGCACATGAGC; Itpr1_MS_gRNA _2 5’-
CACCGAGGGGTAGGAGACGTGCTC), and their synthesis and microinjection was 
performed essentially as previously described (ref.2).  Immunohistochemical analyses was 
performed on embryos with concordant genotypes - apparently heterozygous mutation or a 
wild type allele.  The sections were stained using in-house anti-Pax6 monoclonal antibodies, 
AD1.5.6 and AD2.3.7 using standard immunohistochemical techniques (details available on 
request) with DAPI counterstain. The top panels are shown at 10x magnification and the 
boxed regions of the developing iris and ciliary body are shown at 63x magnification below.  
No difference was discerned between the mutant and wild-type eyes at this stage of 
development. B. Photographs obtained using a slip lamp of the right eye of one male and 
one female 76-day old mice heterozygous for Itpr1 null mutations, with two sex-matched 
littermate controls.  In the middle and lower panels are 5x and 10x magnification of 7uM 
sections of the right eyes of the mutant mice and one control. No major anomalies were 
seen on microscopy of the iris.      
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Quantification of ITPR1 using Imaris v8.1  (Oxford Instruments). A. Raw Structured 
Illumination Microscopy (SIM) images, Nuceli are labelled using DAPI in blue, ITPR1 in 
green, Lamin A/C in Red. B. Total ITPR1 was measured by smoothing images and selecting 
ITPR1 above the local background. C Reticulated ITPR1 was defined as ITPR1-positive 
structures larger than 700nm in any direction, ITPR1-positive foci smaller than this were 
excluded from analysis. D. Nuclear ITPR-1 was defined as ITPR1 co-localised with DAPI 
and was within the LaminA/c stained nuclear envelope. Intranuclear ITPR is shown in cyan. 
E. A second mask high-intensity DAPI staining was generated, (High Dapi Mask). Nuclear 
ITPR outwith this mask is shown in magenta. F. Composite view of the ITPR1 populations 
used for quantification; Reticulated ITPR1 (green), Nuclear ITPR1 (cyan), ITPR1 in low DAPI 
stained areas (Magenta). The nuclear mask is shown in Blue. Scale bar = 1m. G. Graph of 
the number of ITPR1-positive immunofluorescent foci using multiple cells from two 
lymphoblastoid cell lines per genotype .  Fluorescent levels are derived from DAPI and 
secondary antibody conjugates.  The primary antibodies were Itpr1 mouse monoclonal 
antibody  (Life Technologies ab166871, 1:100) and Lamin A/C affinity purified goat 
polyclonal antibody sc-6216 (Santa Cruz Biotechnology, Inc, 1:1000).  Structured 
Illumination Microscopy (SIM) was performed on an Eclipse Ti inverted microscope 
equipped with a Nikon Plan Apo TIRF 100x objective (NA 1.49, oil immersion) and an Andor 
DU-897X-5254 camera.  Laser lines used were 405nm (blue), 488nm (green) and 640nm 
(Far Red). Z-step size for Z stacks was set to 0.120 um. For each focal plane, 15 images (5 
phases, 3 angles) were captured with the NIS-Elements software. SIM image processing, 
reconstruction and analysis were carried out using the N-SIM module of the NIS-Element 
Advanced Research software. In all SIM image reconstructions the Wiener and Apodization 
filter parameters were kept constant. 
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To assess intracellular calcium release we used the agonists ATP (10mM) and anti-Human 
IgM (50g/ml) added to control and test cell lines. The control cells were labelled with Dil 
and test cells with Did using the Vybrant kit (Molecular Probes Inc, Eugene, USA). Control 
and test cell lines were mixed prior to loading with 2M of the ratiometric calcium indicator 
Indo-1. Histograms show cell counts over the ratio of Indo-1 fluorescence emission at 
405nm and 488nm following excitation with a 355nm laser. In each histogram, populations of 
untreated cells (light blue), cells treated (orange in both panels) with either 10mM ATP (left 
panel) or 50g/ml anti-IgM (right panel) and cells treated with 4M of the calcium ionophore 
A23187 (red, positive control) are shown (ref.3, ref.4). Data are representative of all 
available ITPR1-mutant cell lines of a particular ITPR1 genotype (p.Gly2539Arg or 
p.Lys2596del). Each cell line was assessed in two independent experiments per agonist.  
No differences were seen between mutant and control cell lines using either agonist. 

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The recently published cryoelectron microscopy structure of the tetrameric ITPR1 channel 
(PDB ID: 3JAV) was refined using MODELLER to add missing side chains to the C 
backbone. Twenty FoldX replicates were performed for each pathogenic ITPR1 mutation 
(except Val1547Met, which is not present in the structure). Since FoldX does not predict the 
effects of deletions, we approximated the effects of Lys2596del with a glycine mutation. 
Although the effects of a deletion can potentially be much different than a glycine mutation, 
the small predicted effect of the K>G mutation suggests that mutations at this position may 
be structurally mild. 
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 ITPR1_ex48F GTAGCGCGACGGCCAGTCCTCCCATGTGCCAGTTG 
ITPR1_ex54F GTAGCGCGACGGCCAGTGTGTGAGATGCTCTCGTTGC 
ITPR1_ex55F GTAGCGCGACGGCCAGTAAACCAAGTTTGCATTATGGG 
ITPR1_ex56F GTAGCGCGACGGCCAGTTTAATCAGCCGTGAATTGGG 
ITPR1_ex57F GTAGCGCGACGGCCAGTGATGGCATTCAGGAAACAGG 
ITPR1_ex58F GTAGCGCGACGGCCAGTCCCAGACTGATCCAGACACC 
ITPR1_ex48R CAGGGCGCAGCGATGACAAGCTCCAGGAAGCAGATCC 
ITPR1_ex54R CAGGGCGCAGCGATGACAGGGTCTGTGATGAGAGAGAGG 
ITPR1_ex55R CAGGGCGCAGCGATGACCGTGTTAGGGAGATACAATGGG 
ITPR1_ex56R CAGGGCGCAGCGATGACTCTTCTTCCAACATCACCTGC 
ITPR1_ex57R CAGGGCGCAGCGATGACTACACTCAACACCGCTGCAT 
ITPR1_ex58R CAGGGCGCAGCGATGACATCACACCCTCGCAGTATCC 
! 
 
m_Itpr1_ex57F CCCCTCCTGTCTTAACTGTG 
m_Itpr1_ex57Ra CTGCCTGTCCCCACAAGCC 
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e  g. c.  p. 
ExAC 
allele 
count 
phenotype inheritance PolyPhen2 (score)  SIFT (score) MutationTaster  Align GVGD 
ITPR1 hg19 Chr3:4687357-4687357 800C>T Thr267Met 0 
SCA29, 
cerebellar ataxia 
heterozygous de 
novo 
PROBABLY 
DAMAGING (1.000) 
Deleterious 
(0) 
Disease causing 
(prob value: 0.999) 
Class C65 (GV: 0.00 
- GD: 81.04) 
ITPR1 hg19 Chr3:4687357-4687357 800C>G Thr267Arg 0 cerebellar ataxia 
heterozygous de 
novo 
PROBABLY 
DAMAGING (1.000) 
Deleterious 
(0) 
Disease causing 
(prob value: 0.999) 
Class C65 (GV: 0.00 
- GD: 70.97) 
ITPR1 hg19 Chr3:4687387-
4687387 830G>T  Ser277Ile 0 
SCA29, 
cerebellar ataxia 
heterozygous de 
novo 
PROBABLY 
DAMAGING (0.999) 
Deleterious 
(0) 
Disease causing 
(prob value: 0.999) 
Class C65 (GV: 0.00 
- GD: 141.80) 
ITPR1 hg19 Chr3:4709128-4709128 1736C>T Thr579Ile 0 cerebellar ataxia 
heterozygous de 
novo 
PROBABLY 
DAMAGING (0.998) 
Deleterious 
(0) Disease causing (prob value: 0.999) 
Class C65 (GV: 0.00 
- GD: 89.28) 
ITPR1 hg19 Chr3:4709151-4709151 1759A>G Asn587Asp 0 
SCA29; ataxia 
with ID 
heterozygous de 
novo, familial 
PROBABLY 
DAMAGING (0.958) 
Deleterious 
(0) 
Disease causing 
(prob value: 0.999) Class C15 (GV: 0.00 - GD: 23.01) 
ITPR1 hg19 Chr3:4725156-4725156 3203C>T Pro1068Leu 0 
SCA15, adult-
onset 
heterozygous 
familial 
POSSIBLY 
DAMAGING (0.792) 
Deleterious 
(0) 
Disease causing 
(prob value: 0.999) 
Class C65 (GV: 0.00 
- GD: 97.78) 
ITPR1 hg19 Chr3:4741593-4741594 
4459_446
0delinsGA Ser1487Asp 0 ataxia with ID 
heterozygous de 
novo 
POSSIBLY 
DAMAGING (0.905) 
Deleterious 
(0) Disease causing (prob value: 0.999) 
Class C65 (GV: 0.00 
- GD: 65.47) 
ITPR1 hg19 Chr3:4747877-4747877 4639G>A Val1547Met 
0 SCA29; SCA heterozygous familial BENIGN (0.085) 
Tolerated 
(0.41) 
Disease causing 
(prob value: 0.999) 
Class C15 (GV: 0.00 
- GD: 20.52) 
           
ITPR1 hg19 Chr3:4821267-4821267 6280G>C Glu2094Gln 0 
Gillespie 
syndrome 
heterozygous de 
novo 
PROBABLY 
DAMAGING (0.999) 
Deleterious 
(0.01) 
Disease causing 
(prob value: 1) 
Class C25 (GV: 0.00 
- GD: 29.27) 
ITPR1 
hg19 Chr3:4821268-
4821268 6281A>G Glu2094Gly 0 Gillespie syndrome 
heterozygous 
familial 
PROBABLY 
DAMAGING (0.999) 
Deleterious 
(0) 
Disease causing 
(prob value: 1) 
Class C65 (GV: 0.00 
- GD: 97.85) 
ITPR1 hg19 Chr3:4856205-4856205 7615G>C Gly2539Arg 0 
Gillespie 
syndrome 
heterozygous de 
novo 
PROBABLY 
DAMAGING (0.999) 
Deleterious 
(0) 
Disease causing 
(prob value: 1) 
Class C65 (GV: 0.00 
- GD: 125.13) 
ITPR1 hg19 Chr3:4856205-4856205 7615G>A Gly2539Arg 
1 in 
12071
6 
Gillespie 
syndrome 
heterozygous de 
novo 
PROBABLY 
DAMAGING (0.999) 
Deleterious 
(0) 
Disease causing 
(prob value: 1) Class C65 (GV: 0.00 - GD: 125.13) 
ITPR1 hg19 Chr3:4856866-4856868 
7786_778
8delAAG Lys2596del 0 
Gillespie 
syndrome 
heterozygous de 
novo N/A N/A 
Disease causing 
(prob value: 0.999) N/A 
 
Table S3. Predicted pathogenicity scores for ITPR1 missense mutations. All numbering is based on the nucleotide canonical reference 
sequence NM_001168272.1 (ENST00000302640) and the corresponding protein non-canonical reference sequence NP_001161744.1 
(ENSP00000306253.8; Q14643-2), which represent ITPR1 isoform 2 with a total of 2743 amino acids and lacking the 15 amino acid insertion at 
Asp321 in the ligand transferase domain.  All phenotypes are congenital or early onset unless stated otherwise.  The pathogenicity predictions 
were run from the following sites: PolyPhen2 http://genetics.bwh.harvard.edu, SIFT http://grch37.ensembl.org/Homo_sapiens/Tools/VEP/, 
MutationTaster http://www.mutationtaster.org, and Align GVGD http://agvgd.iarc.fr/agvgd (all run on 8 Feb 2016). SCA, spinocerebellar ataxia; 
ID, intellectual disability; N/A, not applicable. 
